The pharmaceuticals firm, backed by industry giants Novartis, Eli Lilly and Astellas, will receive further funding from the US government to jointly develop one of its compounds.
US-based pharmaceuticals company Viamet has been chosen by US government agency The National Institutes of Health (NIH) to develop one of the firm’s antifungal compounds, in return for an undisclosed amount of funding.
In February 2010, Viamet signed a licensing option agreement with Novartis Option Fund, the corporate venturing division of Switzerland-based pharmaceutical conglomerate Novartis, for its Metallophile technology. The agreement included an undisclosed upfront fee, but the deal could potentially see Viamet receiving over $200m in milestone payments…
